{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T02:35:20Z","timestamp":1781231720697,"version":"3.54.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T00:00:00Z","timestamp":1499904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.vaccine.2017.07.013","type":"journal-article","created":{"date-parts":[[2017,7,15]],"date-time":"2017-07-15T21:45:13Z","timestamp":1500155113000},"page":"4621-4628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"PB","title":["Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: A phase I\/II randomized trial"],"prefix":"10.1016","volume":"35","author":[{"given":"Anuradha","family":"Madan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Sheldon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Frenette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Friel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamadou","family":"Drame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L.","family":"Innis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Schuind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.07.013_b0005","first-page":"469","article-title":"Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness","volume":"86","author":"World Health Organization (WHO)","year":"2011","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2017.07.013_b9005","unstructured":"World Health Organization (WHO). Influenza at the human-animal interface. Summary and assessment, <http:\/\/www.who.int\/influenza\/human_animal_interface\/Influenza_Summary_IRA_HA_interface_01_16_2017_FINAL.pdf?ua=1>; 20 December to 16 January 2017. [accessed on 1 March 2017]."},{"key":"10.1016\/j.vaccine.2017.07.013_b0010","doi-asserted-by":"crossref","first-page":"9679","DOI":"10.1128\/JVI.75.20.9679-9686.2001","article-title":"Cocirculation of avian H9N2 and contemporary \u201chuman\u201d H3N2 influenza A viruses in pigs in southeastern China: potential for genetic reassortment?","volume":"75","author":"Peiris","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.07.013_b0015","first-page":"100","article-title":"Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses and candidate vaccine viruses developed for potential use in human vaccines - February 2010","volume":"85","author":"World Health Organization (WHO)","year":"2010","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2017.07.013_b0020","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1086\/508174","article-title":"Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A\/H9N2 vaccine preparations","volume":"43","author":"Atmar","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.013_b0025","doi-asserted-by":"crossref","first-page":"8066","DOI":"10.1016\/j.vaccine.2011.08.044","article-title":"Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine","volume":"29","author":"Atmar","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.013_b0030","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00430-002-0147-9","article-title":"Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines","volume":"191","author":"Hehme","year":"2002","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2017.07.013_b0035","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/596558","article-title":"A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults","volume":"199","author":"Karron","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.013_b0040","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.vaccine.2009.09.103","article-title":"Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A\/H9N2 vaccine formulations","volume":"28","author":"Nicholson","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.013_b0045","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/S0140-6736(03)15014-3","article-title":"Safety and antigenicity of whole virus and subunit influenza A\/Hong Kong\/1073\/99 (H9N2) vaccine in healthy adults: phase I randomised trial","volume":"362","author":"Stephenson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.07.013_b0050","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1128\/CVI.00275-14","article-title":"Phase I\/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults","volume":"22","author":"Aichinger","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.07.013_b0055","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4161\/hv.8.1.18859","article-title":"New technologies for influenza vaccines","volume":"8","author":"Dormitzer","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.07.013_b0060","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/infdis\/jir172","article-title":"Dose-sparing H5N1 A\/Indonesia\/05\/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study","volume":"203","author":"Langley","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.013_b0065","doi-asserted-by":"crossref","first-page":"e1003657","DOI":"10.1371\/journal.ppat.1003657","article-title":"New world bats harbor diverse influenza A viruses","volume":"9","author":"Tong","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2017.07.013_b0070","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1073\/pnas.1116200109","article-title":"A distinct lineage of influenza A virus from bats","volume":"109","author":"Tong","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2017.07.013_b0075","doi-asserted-by":"crossref","first-page":"7639","DOI":"10.1073\/pnas.78.12.7639","article-title":"Sequence relationships among the hemagglutinin genes of 12 subtypes of influenza A virus","volume":"78","author":"Air","year":"1981","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2017.07.013_b0080","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/0042-6822(91)90588-3","article-title":"Comparison of complete amino acid sequences and receptor-binding properties among 13 serotypes of hemagglutinins of influenza A viruses","volume":"182","author":"Nobusawa","year":"1991","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.07.013_b0085","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0140-6736(99)03311-5","article-title":"Human infection with influenza H9N2","volume":"354","author":"Peiris","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.07.013_b0090","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1086\/652701","article-title":"Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1\/2 trial in adults","volume":"201","author":"Langley","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.013_b0095","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa1315727","article-title":"Efficacy of high-dose versus standard-dose influenza vaccine in older adults","volume":"371","author":"DiazGranados","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.07.013_b0100","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/infdis\/jiu173","article-title":"Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial","volume":"210","author":"Nolan","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.013_b0105","doi-asserted-by":"crossref","unstructured":"The SJCEIRS H9 Working Group. Assessing the fitness of distinct clades of influenza A (H9N2) viruses. Emerg Microbes Infect 2013; 2: e75.","DOI":"10.1038\/emi.2013.75"},{"key":"10.1016\/j.vaccine.2017.07.013_b0110","doi-asserted-by":"crossref","first-page":"5","DOI":"10.15226\/2473-2176\/1\/1\/00105","article-title":"Antigenically and Genetically Diverse Isolates of Low Pathogenicity H9N2 Avian Influenza Virus Provide Cross-Clade Vaccinal Protection","volume":"1","author":"Davidson","year":"2016","journal-title":"Int J Vaccine Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1730909X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1730909X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T05:50:51Z","timestamp":1535608251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1730909X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":23,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0264410X1730909X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.013","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: A phase I\/II randomized trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 GlaxoSmithKline Biologicals. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}